Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

NETWORK 2OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Lymphoma 142Leukemia 111Leukemia, Myeloid, Acute 100Precursor Cell Lymphoblastic Leukemia-Lymphoma 93Lymphoma, Non-Hodgkin 91Multiple Myeloma 88Lymphoma, Large B-Cell, Diffuse 80Myelodysplastic Syndromes 74Lymphoma, Follicular 73Lymphoma, Mantle-Cell 72Leukemia, Lymphocytic, Chronic, B-Cell 69Burkitt Lymphoma 67Hodgkin Disease 66Lymphoma, Large-Cell, Immunoblastic 60Lymphoma, B-Cell, Marginal Zone 49Breast Neoplasms 48Neoplasms, Plasma Cell 39Leukemia, Myeloid, Accelerated Phase 34Leukemia, Myeloid, Chronic-Phase 33Recurrence 32Myeloproliferative Disorders 32Ovarian Neoplasms 31Congenital Abnormalities 30Blast Crisis 30Sarcoma 28Dendritic Cell Sarcoma, Interdigitating 28Central Nervous System Neoplasms 28Leukemia, Myelomonocytic, Chronic 27Neuroblastoma 25Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 21

Interventions

Paclitaxel 7Doxorubicin 5pembrolizumab 4pazopanib 4Gemcitabine 4Bevacizumab 4durvalumab 3Radiotherapy 3Propranolol 3Docetaxel 3regorafenib 2cemiplimab 2Surveys and Questionnaires 2Sunitinib 2Standard of Care 2Nivolumab 2Ifosfamide 23-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2zanidatamab 1veliparib 1tucatinib 1trilaciclib 1tremelimumab 1trebananib 1trastuzumab duocarmazine 1talimogene laherparepvec 1talazoparib 1spartalizumab 1sintilimab 1selinexor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Hemangiosarcoma × Filgrastim × Clear all
NCT05799612 2026-02-13

Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma

M.D. Anderson Cancer Center

Phase 1 Withdrawn
Sarcoma

Hemangiosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡